Print this page    •   Back to Web version of article

News Briefs
Herpes Vaccine Trial Needs 7,500 Women

November 26, 2002

For a new vaccine trial, the National Institute of Allergy and Infectious Diseases is working with GlaxoSmithKline to find a rare population of women -- those who have never been infected with genital herpes or the cold sore virus, both of which are incredibly common. Researchers hope the new vaccine will win approval based on the trial's results. "More than 1 million new cases of genital herpes are diagnosed in the United States each year," NIAID Director Dr. Anthony Fauci said last week. The trial was set up just a day after researchers confirmed the vaccine can prevent up to 70 percent of genital herpes infections among women; it does not seem to work for men, however. For more information about the trial, visit www.niaid.nih.gov/dmid/stds/herpevac/.

Back to other CDC news for November 26, 2002

Previous Updates

Excerpted from:
Detroit Free Press
11.26.02




This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. You can find this article online by typing this address into your Web browser:
http://www.thebody.com/content/art18745.html

General Disclaimer: TheBody.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBody.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.